Pharmaceutical intermediates
Dapagliflozin Intermediates
7 pharmaceutical intermediates for Dapagliflozin. Indication: Chronic Renal Insufficiency; Heart Failure; Renal Disease; Type 2 Diabetes Mellitus (T2DM); Type 1 Diabetes Mellitus (T1DM).
About Dapagliflozin
- Originator
- Boehringer Ingelheim
- Indication
- Chronic Renal Insufficiency; Heart Failure; Renal Disease; Type 2 Diabetes Mellitus (T2DM); Type 1 Diabetes Mellitus (T1DM)
- Approved Date
- 10/29/2014
- DS/DP
- 10/04/2025
Available intermediates
7 intermediates currently listed for Dapagliflozin. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-Bromo-2-chlorobenzoic acid | 21739-92-4 | / | / |
| (5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone | 461432-22-4 | / | / |
| 4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether | 461432-23-5 | / | / |
| 1-Chloro-2-(4-ethoxybenzyl)-4-iodobenzene | 1103738-29-9 | / | / |
| 2,3,4,6-Tetrakis-0-trimethylsilyl-D-gluconolactone | 32384-65-9 | / | / |
| (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]pheny!]D-glucitol tetraacetate | 461432-25-7 | / | / |
| (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)-2-Methoxytetrahydro-2H-pyran-3,4,5-triol | 714269-57-5 | / | / |
Building toward Dapagliflozin?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →